Marika Nestor
Overview
Explore the profile of Marika Nestor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
584
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lundgren Mortensen A, Berglund H, Jha P, Stenman A, Selvaraju R, Lundqvist H, et al.
Mol Cancer Ther
. 2025 Feb;
PMID: 39976160
Anaplastic thyroid cancer (ATC) is a rare but severe form of thyroid cancer responsible for approximately 50% of thyroid cancer deaths. Consequently, the identification of innovative therapies remains crucial for...
2.
Chandramohan A, Josien H, Yuen T, Duggal R, Spiegelberg D, Yan L, et al.
Nat Commun
. 2025 Feb;
16(1):1617.
PMID: 39948100
No abstract available.
3.
Spiegelberg D, Hwang L, Pua K, Kumar S, Koh X, Koh X, et al.
Sci Rep
. 2025 Jan;
15(1):1000.
PMID: 39762369
About 50% of all cancers carry a mutation in p53 that impairs its tumor suppressor function. The p53 missense mutation p53 (p53 in mice) is a hotspot mutation in various...
4.
Ingelshed K, Melssen M, Kannan P, Chandramohan A, Partridge A, Jiang L, et al.
iScience
. 2024 May;
27(6):109862.
PMID: 38784022
Immunotherapy has revolutionized cancer treatment but its efficacy depends on a robust immune response in the tumor. Silencing of the tumor suppressor p53 is common in tumors and can affect...
5.
Chandramohan A, Josien H, Yuen T, Duggal R, Spiegelberg D, Yan L, et al.
Nat Commun
. 2024 Jan;
15(1):489.
PMID: 38216578
Although stapled α-helical peptides can address challenging targets, their advancement is impeded by poor understandings for making them cell permeable while avoiding off-target toxicities. By synthesizing >350 molecules, we present...
6.
Berglund H, Salomonsson S, Mohajershojai T, Gago F, Lane D, Nestor M
Eur J Nucl Med Mol Imaging
. 2023 Oct;
51(3):768-778.
PMID: 37823909
Purpose: Molecular radiotherapy is a treatment modality that is highly suitable for targeting micrometastases and [Lu]Lu-DOTATATE is currently being explored as a potential novel treatment option for high-risk neuroblastoma. p53...
7.
Mohajershojai T, Spangler D, Chopra S, Frejd F, Yazaki P, Nestor M
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686514
Carcinoembryonic antigen (CEA) has emerged as an attractive target for theranostic applications in colorectal cancers (CRCs). In the present study, the humanized anti-CEA antibody hT84.66-M5A (M5A) was labeled with Lu...
8.
Saren T, Saronio G, Marti Torrell P, Zhu X, Thelander J, Andersson Y, et al.
Nat Commun
. 2023 Aug;
14(1):4732.
PMID: 37563127
Chimeric antigen receptor (CAR)-T cell therapy is rapidly advancing as cancer treatment, however, designing an optimal CAR remains challenging. A single-chain variable fragment (scFv) is generally used as CAR targeting...
9.
Fernandes S, Mohajershojai T, Lundsten S, Sarmento B, Tome J, Nestor M, et al.
J Photochem Photobiol B
. 2023 May;
243:112716.
PMID: 37126865
Photodynamic therapy (PDT) has been used as an alternative or as a complement of conventional approaches for cancer treatment. In PDT, the reactive oxygen species (ROS) produced from the interaction...
10.
Ingelshed K, Spiegelberg D, Kannan P, Pavenius L, Hacheney J, Jiang L, et al.
Cancer Res Commun
. 2023 Mar;
2(9):1075-1088.
PMID: 36922937
Significance: The MDM2 inhibitor Navtemadlin arrests mouse tumor growth and potentiates radiotherapy. Our results support a threshold model for apoptosis induction that requires a high, prolonged p53 signaling for cancer...